MilliporeSigma has introduced its ADC Express services for the rapid production of ADCs, which can reduce the time needed to produce development grade constructs for target molecule identification.
ADC Express services accelerate pre-clinical conjugate candidate selection as part of a comprehensive portfolio of services that reduces overall time to clinic from pre-clinical to commercial.
MilliporeSigma’s platform technology can efficiently turn an antibody, linker and payload into an ADC. The company offers a platform approach to ADC constructs and bioconjugation, resulting in increased flexibility and speed.
ADC Express services include:
- Mini-prep scale: 10–20 mg ADC construct ± column purification
- Medium-prep scale: ~100 mg ADC ± column purification
- Certificate of testing with key quality attributes, including ADC concentration, payload density/DAR (drug antibody ratio) and monomer/aggregate content and free residual payload
For companies that have a rich pipeline of monoclonal antibodies (mAbs) and want to enter the ADC space, MilliporeSigma’s ADC Express services allows them to obtain ADCs without having to invest in potent handling capabilities. Companies can either bring their own linker technology or procure a linker payload from MilliporeSigma.
MilliporeSigma’s ADC service portfolio combines the crucial steps of drug development and production: mAb solutions, linker, payload and the final conjugation — all from a single source.